Day ThreeWednesday, 21 May 2025 - ET (Eastern Time, GMT-05:00)

Manufacturers increasingly seek comprehensive assessments of their GP Compliance Programs. Rather than traditional evaluations, we've developed a collaborative "GP Enhancement Project" approach. This iterative process involves deep-diving into documentation, methodology, and calculations while working alongside manufacturers to implement improvements in real-time. Learn how this partnership model helps companies build sustainable GP Compliance Programs with confidence.

• Master evolving competitive dynamics between originators, biosimilars, and generics - examining real-world pricing strategies, PBM pressures, and channel optimization approaches across product types

• Balance profitability amid complex government program requirements, wholesaler fee structures, and membership validation challenges unique to biosimilar and generic business models

• Optimize operational execution across distribution channels while managing intricate chargeback processes and contract pharmacy relationships in an increasingly competitive landscape

• Analyze how IRA implementation, Medicare Part D redesign, and emerging PBM policies are reshaping market access opportunities and contracting approaches for non-brand manufacturers

• Future-proof your strategy by understanding shifting payor dynamics, regulatory requirements, and market entrant impacts on biosimilar and generic positioning

Join fellow senior leaders for an elevated lunch experience where you'll engage in facilitator-guided conversations on mission-critical topics impacting pharmaceutical manufacturers in 2025, including IRA implementation impacts, evolving PBM dynamics, state-level policy shifts, and strategic GTN management. This closed-door session provides a confidential environment for authentic dialogue and solution sharing.

Invitation-only gathering limited to 35 participants. Email katelyn.reichheld@informa.com for more details.